PURE BIOSCIENCE, INC.
For the period ended Jul 31, 2025. Filed Oct 29, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Oct 29, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| PURE BIOSCIENCE, INC. | DATE |
|---|---|
| /s/ Robert Bartlett | October 29, 2025 |
| Robert Bartlett | |
| President and Chief Executive Officer | |
Power of Attorney
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Robert Bartlett and Mark Elliott, and each of them, as his true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him and in his name, place and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his substitutes, may lawfully do or cause to be done by virtue thereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, this report is signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| NAME | TITLE | DATE |
|---|---|---|
| /s/ ROBERT BARTLETT | President, Chief Executive Officer, Director | October 29, 2025 |
| Robert Bartlett | Principal Executive Officer | |
| /s/ MARK ELLIOTT | Vice President, Finance | October 29, 2025 |
| Mark Elliott | Principal Financial and Accounting Officer | |
| /s/ IVAN CHEN | Chairman of the Board | October 29, 2025 |
| Ivan Chen | ||
| /s/ TOM MYERS | Director | October 29, 2025 |
| Tom Myers | ||
| /s/ DAVID RENDALL | Director | October 29, 2025 |
| David Rendall | ||
| /s/ TOM Y. LEE | Director | October 29, 2025 |
| Tom Y. Lee | ||
| /s/ BERNARD BLOTNER | Director | October 29, 2025 |
| Bernard Blotner | ||
| /s/ DARIN ZEHR | Director | October 29, 2025 |
| Darin Zehr | ||
Index to Consolidated Financial Statements
| Report of Independent Registered Public Accounting Firm PCAOB ID NO: 572 | F-2 |
|---|---|
| Consolidated Balance Sheets as of July 31, 2025 and 2024 | F-3 |
| Consolidated Statements of Operations for the years ended July 31, 2025 and 2024 | F-4 |
| Consolidated Statements of Stockholders’ Equity for the years ended July 31, 2025 and 2024 | F-5 |
| Consolidated Statements of Cash Flows for the years ended July 31, 2025 and 2024 | F-6 |
| Notes to Consolidated Financial Statements | F-7 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.